OS Therapies Announces Completion Of Phase 2b Clinical Trial For OST-HER2 In Recurred Osteosarcoma; Preparing To Request FDA Type C Meeting And Adjust Protocol; Data Analysis And Topline Results Expected In Q4 2024
Portfolio Pulse from Benzinga Newsdesk
OS Therapies has completed a Phase 2b clinical trial for OST-HER2 in recurred osteosarcoma and is preparing to request an FDA Type C meeting. The company expects data analysis and topline results in Q4 2024. OS Therapies will ring the NYSE closing bell today, and CEO Paul Romness will appear on Fintech.TV and Schwab Network.
October 03, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
OS Therapies has completed a Phase 2b trial for OST-HER2, a treatment for recurred osteosarcoma, and is preparing for an FDA Type C meeting. The company will ring the NYSE closing bell today.
The completion of a Phase 2b trial is a significant milestone for OS Therapies, indicating progress in their drug development pipeline. Preparing for an FDA meeting suggests potential regulatory advancements. The NYSE bell ringing event may increase visibility and investor interest.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90